Hematologic Abnormalities After Oral Trimethoprim-Sulfamethoxazole Therapy in Children FREE

Basim I. Asmar, MD; Sajid Maqbool, MD; Adnan S. Dajani, MD

Read in part before the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Sept 22, 1980.

Reprint requests to Division of Infectious Diseases, Children's Hospital of Michigan, 3901 Beaubien Blvd, Detroit, MI 48201 (Dr Asmar).

Am J Dis Child. 1981;135(12):1100-1103. doi:10.1001/archpedi.1981.02130360008004.

Text Size: A A A

Published online

Article

References

Comments

ABSTRACT

ABSTRACT | REFERENCES

• The development of hematologic abnormalities was prospectively evaluated in 50 children treated for ten days each with oral trimethoprim-sulfamethoxazole and compared with a control group of 20 children with similar infections treated with amoxicillin trihydrate. Neutropenia (polymorphonuclear neutrophilic leukocyte count, ≤ 1,500/cu mm) developed in 17 (34%) of the 50 children treated with trimethoprim-sulfamethoxazole compared with one (5%) in the control group of 20 children (P <.001). Thrombocytopenia (platelet count, < 150,000/cu mm) developed in six (12%) of the children treated with trimethoprim-sulfamethoxazole, but it did not develop in any of the amoxicillin-treated children (P <.01). Neutropenia occurred mostly during the first week of treatment and lasted a mean of 8.9 days. Thrombocytopenia was noted between the seventh and 16th day (mean, 10.3 days) and lasted a mean of 12.7 days. Both side effects resolved spontaneously without ill effects. Children treated with oral trimethoprim-sulfamethoxazole should be followed up with biweekly leukocyte and platelet counts, and treatment should be discontinued if severe neutropenia or thrombocytopenia develops.

(Am J Dis Child 1981;135:1100-1103)

REFERENCES

ABSTRACT | REFERENCES

Hitchings GH: Biochemical background of trimethoprim-sulfamethoxazole . Med J Aust 1973;;1( (suppl) ):5-9.

Forbes PA, Drummond KN: Trimethoprim-sulfamethoxazole in recurrent urinary tract infection in children . J Infect Dis 1973;; 128( (suppl) ):626-628.

Japan cooperative clinical study group for co-trimoxazole: Trimethoprim-sulfamethoxazole in the treatment of bacterial infections: Report of clinical trials in Japan. J Infect Dis 1973;;128( (suppl) ):629-635.

Salter AJ: The toxicity profile of trimethoprim/sulfamethoxazole after four years of widespread use . Med J Aust 1973;;1( (suppl) ):70-74.

Worsmer JP, Keusch GT: Trimethoprim-sulfamethoxazole in the United States . Ann Intern Med 1979;;91:420-429.

Ardati KO, Thirumoorthi MC, Dajani AS: Intravenous trimethoprim-sulfamethoxazole in the treatment of serious infections in children . J Pediatr 1979;;95:801-806.

Harker LA, Finch C: Thrombokinetics in man . J Clin Invest 1969;;48:963-974.

Golde DW, Bersch N, Quan SG: Trimethoprim and sulfamethoxazole inhibition of haematopoiesis in vitro . Br J Haematol 1978;;40:363-367.

Bose W, Linzenmeier G, Karama A, et al: Controlled trial of co-trimoxazole in children with urinary tract infection: Bacteriologic efficacy and haematological toxicity . Lancet 1974;;2:614-616.

Bradley PP, Warden GD, Maxwell JG, et al: Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole . Ann Intern Med 1980;;93:560-562.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal